Molecular and functional imaging of invasion and metastasis: Windows into the metastatic cascade

Cancer Biomarkers

Volumn 7, Issue 4-5, 2010, Pages 173-188

  Stasinopoulos, Ioannis ^a   Penet, Marie France ^a   Krishnamachary, Balaji ^a   Bhujwalla, Zaver M ^a,b  

^a JHU ICMIC Program   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Invasion; metastasis; molecular and functional imaging; theranostics of metastasis

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GELATINASE B; GREEN FLUORESCENT PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; INDOMETACIN; K RAS PROTEIN; LAPATINIB; MATRILYSIN; PLERIXAFOR; SMALL INTERFERING RNA; VASCULOTROPIN RECEPTOR 1;

ARTICLE; BASEMENT MEMBRANE; BIOLUMINESCENCE; BONE MARROW CELL; BONE METASTASIS; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER INVASION; CANCER LOCALIZATION; CANCER SIZE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; DISTANT METASTASIS; DRUG UPTAKE; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROBLAST; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; LYMPH NODE METASTASIS; MACROPHAGE; MELANOMA; MESENCHYMAL STEM CELL; METASTASIS; MICROVASCULATURE; MOLECULAR IMAGING; NONHUMAN; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT;

ANIMALS; HUMANS; MOLECULAR IMAGING; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS;

EID: 79955591564     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2010-0188     Document Type: Article

References (110)

1. S. Dorudi and I.R. Hart, Mechanisms underlying invasion and metastasis, Curr Opin Oncol 5 (1993), 130-135. (Pubitemid 23037421)
2. T. Meyer and I.R. Hart, Mechanisms of tumour metastasis, Eur J Cancer 34 (1998), 214-221. (Pubitemid 28189189)
3. G.P. Gupta and J. Massague, Cancer metastasis: building a framework, Cell 127 (2006), 679-695. (Pubitemid 44781029)
4. C Coghlin and G.I. Murray, Current and emerging concepts in tumour metastasis, J Pathol 222 (2010), 1-15.
5. C.A. Klein, Parallel progression of primary tumours and metastases, NatRev Cancer 9 (2009), 302-312.
6. J.A. Schardt, M. Meyer, C.H. Hartmann, F. Schubert, O. Schmidt-Kittler, C Fuhrmann, B. Polzer, M. Petronio, R. Eils and C.A. Klein, Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer, Cancer Cell 8 (2005), 227-239. (Pubitemid 41317593)
7. O. Schmidt-Kittler, T. Ragg, A. Daskalakis, M. Granzow, A. Ahr, T.J. Blankenstein, M. Kaufmann, J. Diebold, H. Arn-holdt, P. Muller, J. Bischoff, D. Harich, G. Schlimok, G. Ri-ethmuller, R. Eils and C.A. Klein, From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression, Proc Natl Acad Sci USA 100 (2003), 7737-7742. (Pubitemid 36760039)
8. R. Dent, M. Trudeau, K.I. Pritchard, W.M. Hanna, H.K. Kahn, C.A. Sawka, L.A. Lickley, E. Rawlinson, P. Sun and S.A. Narod, Triple-negative breast cancer: clinical features and patterns of recurrence, Clin CancerRes 13 (2007), 4429-4434. (Pubitemid 47219710)
9. S. Paget, Distribution of secondary growths in cancer of the breast, TheLancet (1989), 571-573.
10. M. Mendoza and C Khanna, Revisiting the seed and soil in cancer metastasis, Int JBiochem Cell Biol 41 (2009), 1452-1462.
11. J.A. Joyce and J.W. Pollard, Microenvironmental regulation of metastasis, Nat Rev Cancer 9 (2009), 239-252.
12. J.E. Talmadge and I.J. Fidler, AACR centennial series: the biology of cancer metastasis: historical perspective, Cancer Res 70 (2010), 5649-5669.
13. R.D. Cardiff, The pathology of EMT in mouse mammary tumorigenesis, J Mammary GlandBiolNeoplasia 15 (2010), 225-233.
14. D. Tarin, E.W. Thompson and D.F. Newgreen, The fallacy of epithelial mesenchymal transition in neoplasia, Cancer Res 65 (2005), 5996-6000; discussion 6000-1. (Pubitemid 40994379)
15. E.W. Thompson, D.F. Newgreen and D. Tarin, Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res 65 (2005), 5991-5995; discussion 5995. (Pubitemid 40994377)
16. J.S. Fang, R.D. Gillies and R.A. Gatenby, Adaptation to hy-poxia and acidosis in carcinogenesis and tumor progression, Semin Cancer Biol 18 (2008), 330-337.
17. E.C. Finger and A.J. Giaccia, Hypoxia, inflammation, and the tumor microenvironment in metastatic disease, Cancer Metastasis Rev 29 (2010), 285-293.
18. B. Krishnamachary, S. Berg-Dixon, B. Kelly, F. Agani, D. Feldser, G. Ferreira, N. Iyer, J. LaRusch, B. Pak, P. Taghavi and G.L. Semenza, Regulation of colon carcinoma cell inva-sion by hypoxia-inducible factor 1, Cancer Res 63 (2003), 1138-1143. (Pubitemid 36278449)
19. G.L. Semenza, Targeting HIF-1 for cancer therapy, Nat Rev Cancer 3 (2003), 721-732. (Pubitemid 37328811)
20. S.D. Young, R.S. Marshall and R.P. Hill, Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells, Proc Natl Acad Sci U SA 85 (1988), 9533-9537. (Pubitemid 19027161)
21. R. Ravi, B. Mookerjee, Z.M. Bhujwalla, C.H. Sutter, D. Arte-mov, Q. Zeng, L.E. Dillehay, A. Madan, G.L. Semenza and A. Bedi, Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha, Genes Dev 14 (2000), 34-44. (Pubitemid 30051577)
22. P.H. Maxwell, M.S. Wiesener, G.W. Chang, S.C. Clifford, E.C. Vaux, M.E. Cockman, C.C. Wykoff, C.W. Pugh, E.R. MaherandPJ. Ratcliffe, Thetumoursuppressorprotein VHL targets hypoxia-inducible factors for oxygen-dependent pro-teolysis, Nature 399 (1999), 271-275. (Pubitemid 29246458)
23. W. Zundel, C Schindler, D. Haas-Kogan, A. Koong, F. Kaper, E. Chen, A.R. Gottschalk, H.E. Ryan, R.S. Johnson, A.B. Jefferson, D. Stokoe and A.J. Giaccia, Loss of PTEN facilitates HIF-1-mediated gene expression, Genes Dev 14 (2000), 391-396. (Pubitemid 30131884)
24. C Chen, N. Pore, A. Behrooz, F. Ismail-Beigi and A. Maity, Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia, J Biol Chem 276 (2001), 9519-9525.
25. E. Laughner, P. Taghavi, K. Chiles, PC Mahon and G.L. Se-menza, HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha(HIF-1alpha) synthesis: novelmech-anism for HIF-1-mediated vascular endothelial growth factor expression, Mol CellBiol 21 (2001), 3995-4004. (Pubitemid 32476461)
26. D.E. Richard, E. Berra, E. Gothie, D. Roux and J. Pouysse-gur, p42/p44 mitogen-activated protein kinases phosphory-late hypoxia-inducible factor 1alpha (HIF-1alpha) and en-hance the transcriptional activity of HIF-1, J Biol Chem 274 (1999), 32631-32637. (Pubitemid 129535289)
27. N.M. Mazure, E.Y. Chen, K.R. Laderoute and A.J. Giaccia, Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signal-ing pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element, Blood 90 (1997), 3322-3331. (Pubitemid 27473400)
28. D.G. Dudaand R.K. Jain, Premetastatic lung niche: is vascu-lar endothelial growth factor receptor 1 activation required? Cancer Res 70 (2010), 5670-5673.
29. R.N. Kaplan, S. Rafii and D. Lyden, Preparing the soil: the premetastatic niche, Cancer Res 66 (2006), 11089-11093.
30. S. Hiratsuka, K. Nakamura, S. Iwai, M. Murakami, T Itoh, H. Kijima, J.M. Shipley, R.M. Senior and M. Shibuya, MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis, Cancer Cell 2 (2002), 289-300. (Pubitemid 41043963)
31. R.N. Kaplan, R.D. Riba, S. Zacharoulis, A.H. Bramley, L. Vincent, C Costa, D.D. MacDonald, D.K. Jin, K. Shido, S.A. Kerns, Z. Zhu, D. Hicklin, Y Wu, J.L. Port, N. Altorki, E.R. Port, D. Ruggero, S.V. Shmelkov, K.K. Jensen, S. Rafii and D. Lyden, VEGFR1-positive haematopoietic bone mar-row progenitors initiate the pre-metastatic niche, Nature 438 (2005), 820-827. (Pubitemid 41753060)
32. M. Balic, H. Lin, L. Young, D. Hawes, A. Giuliano, G. Mc-Namara, R.H. Datar and R.J. Cote, Most early disseminated cancer cells detected in bone marrow of breast cancer pa-tients have a putative breast cancer stem cell phenotype, Clin Cancer Res 12 (2006), 5615-5621. (Pubitemid 44629587)
33. M.S. Wicha, Cancer stem cells andmetastasis: lethal seeds, Clin Cancer Res 12 (2006), 5606-5607. (Pubitemid 44629584)
34. M.F. Penet, A.P. Pathak, V Raman, P. Ballesteros, D. Artemov and Z.M. Bhujwalla, Noninvasive multiparamet-ric imaging of metastasis-permissive microenvironments in a human prostate cancer xenograft, Cancer Res 69 (2009), 8822-8829.
35. M. Oser and J. Condeelis, The cofilin activity cycle in lamel-lipodia and invadopodia, J Cell Biochem 108 (2009), 1252-1262.
36. J.D. Holland, M. Kochetkova, C Akekawatchai, M. Dottore, A. Lopez and S.R. McColl, Differential functional activation of chemokine receptor CXCR4 is mediated by G proteins in breast cancer cells, Cancer Res 66 (2006), 4117-4124.
37. H. Yamaguchi, M. Lorenz, S. Kempiak, C Sarmiento, S. Coniglio, M. Symons, J. Segall, R. Eddy, H. Miki, T Takenawa and J. Condeelis, Molecular mechanisms of in-vadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin, J Cell Biol 168 (2005), 441-452. (Pubitemid 40205066)
38. S. Prag, M. Parsons, M.D. Keppler, S.M. Ameer-Beg, P. Bar-ber, J. Hunt, A.J. Beavil, R. Calvert, M. Arpin, B. Vojnovic and T. Ng, Activated ezrin promotes cell migration through recruitment of the GEF Dbl to lipid rafts and preferential downstream activation of Cdc42, Mol Biol Cell 18 (2007), 2935-2948. (Pubitemid 47235301)
39. R.K. Vadlamudi, L. Adam, R.A. Wang, M. Mandal, D. Nguyen, A. Sahin, J. Chernoff, M.C. Hung and R. Kumar, Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells, J Biol Chem 275 (2000), 36238-36244.
40. I. Carr and F.W. Orr, Invasion and metastasis, CanMedAssoc J 128(1983), 1164-1167.
41. L. Weiss and P.M. Ward, Cell detachment and metastasis, CancerMetastasisRev2 (1983), 111-127.
42. A. Lochter and M.J. Bissell, Involvement of extracellular matrix constituents in breast cancer, Semin Cancer Biol 6 (1995), 165-173.
43. E. Skrzydlewska, M. Sulkowska, M. Koda and S. Sulkowski, Proteolytic-antiproteolytic balance and its regulation in car-cinogenesis, World J Gastroenterol 11 (2005), 1251-1266. (Pubitemid 40425906)
44. F. Song, K. Wisithphrom, J. Zhou and L.J. Windsor, Ma-trix metalloproteinase dependent and independent collagen degradation, FrontBiosci 11 (2006), 3100-3120. (Pubitemid 43800400)
45. W.Q. Zheng, L.M. Looi and P.L. Cheah, Correlation between laminin and cathepsin D expressions in breast carcinoma, Tumori 88 (2002), 296-299.
46. N. Guinec, V. Dalet-Fumeron and M. Pagano, In vitro study of basement membrane degradation by the cysteine proteinases, cathepsins B, B-like and L. Digestion of collagen IV, laminin, fibronectin, and release of gelatinase activities from basement membrane fibronectin, Biol Chem Hoppe Seyler 374 (1993), 1135-1146. (Pubitemid 2023819)
47. C Li, T.R. Greenwood and K. Glunde, Glucosamine-bound near-infrared fluorescent probes with lysosomal specificity for breast tumor imaging, Neoplasia 10 (2008), 389-398. (Pubitemid 351483579)
48. K. Glunde, S.E. Guggino, M. Solaiyappan, A.P. Pathak, Y. Ichikawa and Z.M. Bhujwalla, Extracellular acidification al-ters lysosomal trafficking in human breast cancer cells, Neo-plasia 5 (2003), 533-545. (Pubitemid 38045090)
49. R. Weissleder, C.H. Tung, U. Mahmood and A. Bogdanov, Jr., In vivo imaging of tumors with protease-activated near-infrared fluorescent probes, Nat Biotechnol 17 (1999), 375-378. (Pubitemid 29166041)
50. J.O. McIntyre, B. Fingleton, K.S. Wells, D.W. Piston, C.C. Lynch, S. Gautam and L.M. Matrisian, Development of a novel fluorogenic proteolytic beacon for in vivo detection and imaging of tumour-associated matrix metalloproteinase-7 activity, Biochem J 377 (2004), 617-628. (Pubitemid 38228373)
51. R.L. Scherer, J.O. McIntyre and L.M. Matrisian, Imaging matrix metalloproteinases in cancer, Cancer Metastasis Rev 27 (2008), 679-690.
52. L. Udabage, G.R. Brownlee, M. Waltham, T. Blick, E.C. Walker, P. Heldin, S.K. Nilsson, E.W. Thompson and T.J. Brown, Antisense-mediated suppression of hyaluronan syn-thase 2 inhibits the tumorigenesis and progression of breast cancer, Cancer Res 65 (2005), 6139-6150. (Pubitemid 40994399)
53. L. Shiftan, T. Israely, M. Cohen, V. Frydman, H. Dafni, R. Stern and M. Neeman, Magnetic resonance imaging visual-ization of hyaluronidase in ovarian carcinoma, Cancer Res 65 (2005), 10316-10323. (Pubitemid 41743724)
54. K.R. Gehlsen and H.N. Wagner, Jr., Hendrix MJ. Membrane invasion culture system (MICS), Med Instrum 18 (1984), 268-271. (Pubitemid 14018915)
55. U. Pilatus, E. Ackerstaff, D. Artemov, N. Mori, R.J. Gillies and Z.M. Bhujwalla, Imaging prostate cancer invasion with multi-nuclear magnetic resonance methods: the Metabolic Boyden Chamber, Neoplasia 2 (2000), 273-279. (Pubitemid 30346083)
56. E. Ackerstaff, B. Gimi, D. Artemov and Z.M. Bhujwalla, Anti-inflammatory agent indomethacin reduces invasion and alters metabolism in a human breast cancer cell line, Neopla-sia 9 (2007), 222-235. (Pubitemid 46457239)
57. W.L. Smith, D.L. DeWitt and R.M. Garavito, Cyclooxyge-nases: structural, cellular, and molecular biology, Annu Rev Biochem 69 (2000), 145-182.
58. A. Greenhough, H.J. Smartt, A.E. Moore, H.R. Roberts, A.C. Williams, C Paraskeva and A. Kaidi, The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment, Carcinogenesis 30 (2009), 377-386.
59. I. Stasinopoulos, N. Mori and Z.M. Bhujwalla, The malig-nant phenotype of breast cancer cells is reduced by COX-2 silencing, Neoplasia 10 (2008), 1163-1169.
60. I. Stasinopoulos, D.R. O'Brien, F. Wildes, K. Glunde and Z.M. Bhujwalla, Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells, Mol Cancer Res 5 (2007), 435-442. (Pubitemid 46903952)
61. L.M. Bernas, PJ. Foster and B.K. Rutt, Magnetic resonance imaging of in vitro glioma cell invasion, J Neurosurg 106 (2007), 306-313. (Pubitemid 46203160)
62. M. Mikhaylova, N. Mori, F.B. Wildes, P. Walczak, B. Gimi and Z.M. Bhujwalla, Hypoxia increases breast cancer cell-induced lymphatic endothelial cell migration, Neoplasia 10 (2008), 380-389.
63. B. Gimi, N. Mori, E. Ackerstaff, E.E. Frost, J.W. Bulte and Z.M. Bhujwalla, Noninvasive MRI of endothelial cell re-sponse to human breast cancer cells, Neoplasia 8 (2006), 207-213. (Pubitemid 43671236)
64. W.R. Zipfel, R.M. Williams and W.W. Webb, Nonlinear mag-ic: multiphoton microscopy inthe biosciences, Nat Biotech-nol21 (2003), 1369-1377. (Pubitemid 37356624)
65. E. Brown, T McKee, E. diTomaso, A. Pluen, B. Seed, Y. Boucher and R.K. Jain, Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic gener-ation, Nat Med 9 (2003), 796-800. (Pubitemid 36749232)
66. T.D. McKee, P. Grandi, W. Mok, G. Alexandrakis, N. Insin, J.P. Zimmer, M.G. Bawendi, Y. Boucher, X.O. Breakefield and R.K. Jain, Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector, Cancer Res 66 (2006), 2509-2513.
67. PP. Provenzano, K.W. Eliceiri, J.M. Campbell, D.R. Inman, J.G. White and PJ. Keely, Collagen reorganization at the tumor-stromal interface facilitates local invasion, BMC Med 4(38) (2006).
68. F. Helmchen and W. Denk, Deep tissue two-photon mi-croscopy, Nat Methods 2 (2005), 932-940.
69. Y Kienast, L. von Baumgarten, M. Fuhrmann, W.E. Klinkert, R. Goldbrunner, J. Herms and F. Winkler, Real-time imaging reveals the single steps of brain metastasis formation, Nat Med16 (2010), 116-22.
70. J.Y. Perentes, T.D. McKee, C.D. Ley, H. Mathiew, M. Daw-son, TP. Padera, L.L. Munn, R.K. Jain and Y Boucher, In vivo imaging of extracellular matrix remodeling by tumor-associated fibroblasts, Nat Methods 6 (2009), 143-145.
71. D. Kedrin, B. Gligorijevic, J. Wyckoff, V.V. Verkhusha, J. Condeelis, J.E. Segall and J. van Rheenen, Intravital imaging of metastatic behavior through a mammary imaging window, NatMethods 5 (2008), 1019-1021.
72. Y.C. Chang, J.Y. Ye, T.P. Thomas, Z. Cao, A. Kotlyar, E.R. Tkaczyk, J.R. Baker Jr and T.B. Norris, Fiber-optic multi-photon flow cytometry in whole blood and in vivo, J Biomed Opt 15 (2010), 047004.
73. W. Wang, J.B. Wyckoff, S. Goswami, Y Wang, M. Sidani, J.E. Segall and J.S. Condeelis, Coordinated regulation of pathways for enhanced cell motility and chemotaxis is con-served in rat and mouse mammary tumors, Cancer Res 67 (2007), 3505-3511. (Pubitemid 46762128)
74. C.H. Contag and M.H. Bachmann, Advances in in vivo bio-luminescence imaging of gene expression, Annu Rev Biomed Eng 4 (2002), 235-260. (Pubitemid 35217421)
75. G.D. Luker and K.E. Luker, Optical imaging: current appli-cations and future directions, JNucl Med 49 (2008), 1-4.
76. H. Sun, S. Pisle, E.R. Gardner and W.D. Figg, Biolumines-cent imaging study: FAK inhibitor, PF-562,271, preclinical study in PC3M-luc-C6 local implant and metastasis xenograft models, Cancer Biol Ther 10 (2010), 38-43.
77. T. Wurdinger, C Badr, L. Pike, R. de Kleine, R. Weissleder, X.O. Breakefield and B.A. Tannous, A secreted luciferase for ex vivo monitoring of in vivo processes, Nat Methods 5 (2008), 171-173. (Pubitemid 351181745)
78. E. Chung, H. Yamashita, P. Au, B.A. Tannous, D. Fukumura and R.K. Jain, Secreted Gaussia luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases, PLoSOne 4 (2009), e8316.
79. R.S. Dothager, K. Flentie, B. Moss, M.H. Pan, A. Kesarwala and D. Piwnica-Worms, Advances in bioluminescence imag-ing of live animal models, Curr Opin Biotechnol 20 (2009), 45-53.
80. C Heyn, J.A. Ronald, S.S. Ramadan, J.A. Snir, A.M. Barry, L.T. MacKenzie, D.J. Mikulis, D. Palmieri, J.L. Bronder, P.S. Steeg, T. Yoneda, I.C. MacDonald, A.F. Chambers, B.K. Rutt and PJ. Foster, In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis tothe brain,Magn Reson Med56 (2006), 1001-1010. (Pubitemid 44691342)
81. G.P. Gupta, D.X. Nguyen, A.C. Chiang, PD. Bos, J.Y Kim, C Nadal, R.R. Gomis, K. Manova-Todorova and J. Mas-sague, Mediators of vascular remodelling co-opted for se-quential steps in lung metastasis, Nature 446 (2007), 765-770. (Pubitemid 46582040)
82. X.H. Zhang, Q. Wang, W. Gerald, C.A. Hudis, L. Norton, M. Smid, J.A. Foekens and J. Massague, Latent bone metas-tasis in breast cancer tied to Src-dependent survival signals, Cancer Cell 16 (2009), 67-78.
83. M. Dietzel, PA. Baltzer, T. Vag, T. Groschel, M. Gajda, O. Camara and W.A. Kaiser, Application of breast MRI for prediction of lymph node metastases-systematic approach using 17 individual descriptors and a dedicated decision tree, Acta Radiol 51 (2010), 885-894
84. N.M. deSouza, S.F. Riches, N.J. Vanas, V.A. Morgan, S.A. Ashley, C Fisher, G.S. Payne and C Parker, Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer, Clin Radiol 63 (2008), 774-782.
85. G.M. Tse, D.K. Yeung, A.D. King, H.S. Cheung and W.T. Yang, In vivo proton magnetic resonance spectroscopy of breast lesions: an update. Breast Cancer Res Treat 104 (2007), 249-255. (Pubitemid 47231271)
86. R. Katz-Brull and H. Degani, Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR ap-plication of the zero trans method, Anticancer Res 16 (1996), 1375-1380.
87. A. Ramirez de Molina, R. Gutierrez, M.A. Ramos, J.M. Silva, J. Silva, F Bonilla, J.J. Sanchez and J.C. Lacal, Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy, Oncogene 21 (2002), 4317-4322. (Pubitemid 34753838)
88. E. Iorio, A. Ricci, M. Bagnoli, M.E. Pisanu, G. Castellano, M. Di Vito, E. Venturini, K. Glunde, Z.M. Bhujwalla, D. Mezzanzanica, S. Canevari and F. Podo, Activation of phos-phatidylcholine cycle enzymes in human epithelial ovarian cancer cells, Cancer Res 70 (2010), 2126-2135.
89. R. Nagarajan, A.M. Gomez, S.S. Raman, D.J. Margolis, T. McClure and M.A. Thomas, Correlation of endorectal 2D JPRESS findings with pathological Gleason scores in prostate cancer patients, NMR Biomed23 (2010), 257-261.
90. M.W. Dewhirst, Y Cao and B. Moeller, Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy re-sponse, NatRev Cancer 8 (2008), 425-437. (Pubitemid 351744964)
91. G. Ren, Z. Miao, H. Liu, L. Jiang, N. Limpa-Amara, A. Mahmood, S.S. Gambhir and Z. Cheng, Melanin-targeted preclinical PET imaging of melanomametastasis, J Nucl Med 50 (2009), 1692-1699.
92. C.M. Deroose, A. De, A.M. Loening, P.L. Chow, P. Ray, A.F. Chatziioannou and S.S. Gambhir, Multimodality imag-ing of tumor xenografts and metastases in mice with com-bined small-animal PET, small-animal CT, and biolumines-cence imaging, J Nucl Med 48 (2007),295-303. (Pubitemid 47555357)
93. T. Schioppa, B. Uranchimeg, A. Saccani, S.K. Biswas, A. Doni, A. Rapisarda, S. Bernasconi, S. Saccani, M. Nebuloni, L. Vago, A. Mantovani, G. Melillo and A. Sica, Regulation of the chemokine receptor CXCR4 by hypoxia, J Exp Med 198 (2003), 1391-1402. (Pubitemid 37392484)
94. A.A. Rose and P.M. Siegel, Emerging therapeutic targets in breast cancer bone metastasis, Future Oncol 6 (2010), 55-74.
95. S. Nimmagadda, M. Pullambhatla, K. Stone, G. Green, Z.M. Bhujwalla and M.G. Pomper, Molecular imaging of CX-CR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography, Cancer Res 70 (2010), 3935-3944.
96. M.G. Harisinghani, J. Barentsz, P.F. Hahn, W.M. Deserno, S. Tabatabaei, C.H. van de Kaa, J. de la Rosette and R. Weissleder, Noninvasive detection of clinically occult lymph-node metastases inprostate cancer, N Engl J Med348 (2003), 2491-2499. (Pubitemid 36706536)
97. R.W. Ross, A.L. Zietman, W. Xie, J.J. Coen, D.M. Dahl, W.U. Shipley, D.S. Kaufman, T. Islam, A.R. Guimaraes, R. Weissleder and M. Harisinghani, Lym-photropic nanoparticle-enhanced magnetic resonance imag-ing (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy, Clin Imaging 33 (2009), 301-305.
98. G. Lin, K.C. Ho, J.J. Wang, K.K. Ng, YY Wai, YT. Chen, C.J. Chang, S.H. Ng, C.H. Lai and T.C. Yen, Detection of lymph node metastasis in cervical and uterine cancers by diffusion-weighted magnetic resonance imaging at 3T, J Magn Reson Imaging 28 (2008), 128-135. (Pubitemid 351956475)
99. B. Goudarzi, R. Kishimoto, S. Komatsu, H. Ishikawa, K. Yoshikawa, S. Kandatsu and T. Obata, Detection of bone metastases using diffusion weighted magnetic resonance imaging: comparison with (1 1)C-methionine PET and bone scintigraphy, Magn Reson Imaging 28 (2010), 372-379.
100. K. Ono, R. Ochiai, T. Yoshida, M. Kitagawa, J. Oma-gari, H. Kobayashi and Y Yamashita, Comparison of diffusion-weighted MRI and 2-[fluorine-18]-fluoro-2- deoxy-D-glucose positron emission tomography (FDG-PET) for de-tecting primary colorectal cancer and regional lymph node metastases, JMagn Reson Imaging 29 (2009), 336-340.
101. S.W. Heijmink, T.W. Scheenen, J.J. Futterer, D.W. Klomp, R.A. Heesakkers, C.A. Hulsbergen-van de Kaa, E.N. van Lin, A. Heerschap and J.O. Barentsz, Prostate and lymph node proton magnetic resonance (MR) spectroscopic imaging with external array coils at 3 T to detect recurrent prostate cancer after radiation therapy, Invest Radiol 42 (2007), 420-427. (Pubitemid 46788742)
102. P. Castellucci, C Fuccio, D. Rubello, R. Schiavina, I. Santi, C Nanni, V. Allegri, G.C. Montini, V. Ambrosini, S. Boschi, G. Martorana, M.C. Marzola and S. Fanti, Is there a role for (11)C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase 1.5 ng/ml? Eur J Nucl Med Mol Imaging 38 (2011) 55-63
103. M. Morikawa, Y. Demura, T. Ishizaki, S. Ameshima, I. Miyamori, M. Sasaki, T. Tsuchida, H. Kimura, Y. Fujibayashi and H. Okazawa, The effectiveness of 18F-FDG PET/CT combined with STIR MRI for diagnosing nodal involvement in the thorax, J NuclMed 50 (2009), 81-87.
104. J.H. Ahn, E.J. Son, J.A. Kim, J.H. Youk, E.K. Kim, J.Y. Kwak, YH. Ryu and J. Jeong, The role of ultrasonography and FDG-PET in axillary lymph node staging of breast can-cer, ActaRadiol 51 (2010), 859-865.
105. O. Dudeck, M. Zeile, C Wybranski, A. Schulmeister, F. Fischbach, M. Pech, G. Wieners, R. Ruhl, O. Grosser, H. Amthauer and J. Ricke, Early prediction of anticancer ef-fects with diffusion-weighted MR imaging in patients with colorectal liver metastases following selective internal radio-therapy, EurRadiol 20 (2010), 2699-2706.
106. H.W. van Laarhoven, D.W. Klomp, M. Rijpkema, YL. Kamm, D.J. Wagener, J.O. Barentsz, C.J. Punt and A. Heer-schap, Prediction of chemotherapeutic response ofcolorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil, NMR Biomed 20 (2007), 128-140. (Pubitemid 46470935)
107. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework, Clin Pharmacol Ther 69 (2001), 89-95.
108. C Li, M.F. Penet, F. Wildes, T Takagi, Z. Chen, PT Win-nard, D. Artemov and Z.M. Bhujwalla, Nanoplex Delivery of siRNA and Prodrug Enzyme for Multimodality Image-Guided Molecular Pathway Targeted Cancer Therapy, ACS Nano 4 (2010), 6707-6716.
109. K. Lee, H. Lee, K.H. Bae and TG. Park, Heparin immobi-lized gold nanoparticles for targeted detection and apoptot-ic death of metastatic cancer cells, Biomaterials 31 (2010), 6530-6536.
110. F. Robert, The potential benefits of low-molecular-weight heparins in cancer patients, J Hematol Oncol 3 (2010), 3.